Adisseo(SH:600299) 光大证券研究·2025-11-05 23:05Core Viewpoint - The company reported stable revenue growth in Q3 2025, driven by increased penetration of liquid methionine and double-digit sales growth in specialty products, despite facing a challenging market environment [4][5]. Group 1: Financial Performance - In the first three quarters of 2025, the company achieved revenue of 12.93 billion, a year-on-year increase of 14%, and a net profit attributable to shareholders of 990 million, a decrease of 1.3% [4]. - For Q3 2025, the company reported revenue of 4.42 billion, up 7.4% year-on-year and 4.9% quarter-on-quarter, while net profit attributable to shareholders was 250 million, down 37% year-on-year and 9% quarter-on-quarter [4]. Group 2: Product Performance - The revenue from functional products in Q3 2025 was 3.275 billion, an increase of 5.5% year-on-year, while specialty products generated revenue of 1.144 billion, up 13.3% year-on-year [5]. - The gross profit for functional and specialty products in Q3 2025 was 760 million and 420 million, respectively, both showing a slight decline of 1% year-on-year [5]. Group 3: Market Position and Expansion - The company is a leading global player in methionine production, with a focus on expanding capacity to meet global demand. A new solid methionine plant with an annual capacity of 150,000 tons is under construction in Quanzhou, expected to be operational by 2027 [6]. - The company is also implementing a debottlenecking expansion project for its liquid methionine plant in Europe, which is set to be fully operational by the end of 2025, further solidifying its market leadership [6].